TY - JOUR T1 - Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting JF - medRxiv DO - 10.1101/2020.08.24.20179457 SP - 2020.08.24.20179457 AU - Laith J. Abu Raddad AU - Hiam Chemaitelly AU - Joel A. Malek AU - Ayeda A. Ahmed AU - Yasmin A. Mohamoud AU - Shameem Younuskunju AU - Houssein H. Ayoub AU - Zaina Al Kanaani AU - Abdullatif Al Khal AU - Einas Al Kuwari AU - Adeel A. Butt AU - Peter Coyle AU - Andrew Jeremijenko AU - Anvar Hassan Kaleeckal AU - Ali Nizar Latif AU - Riyazuddin Mohammad Shaik AU - Hanan F. Abdul Rahim AU - Hadi M. Yassine AU - Mohamed G. Al Kuwari AU - Hamad Eid Al Romaihi AU - Sheikh Mohammad Al Thani AU - Roberto Bertollini Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/28/2020.08.24.20179457.abstract N2 - Background Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is debated. We assessed risk and incidence rate of documented SARS-CoV-2 reinfection in a large cohort of laboratory-confirmed cases in Qatar.Methods All SARS-CoV-2 laboratory-confirmed cases with at least one PCR positive swab that is ≥45 days after a first-positive swab were individually investigated for evidence of reinfection, and classified as showing strong, good, some, or weak/no evidence for reinfection. Viral genome sequencing of the paired first-positive and reinfection viral specimens was conducted to confirm reinfection. Risk and incidence rate of reinfection were estimated.Results Out of 133,266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least one subsequent positive swab ≥45 days after the first-positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between first and reinfection swab was 64.5 days (range: 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only one person was hospitalized at time of reinfection, but still with mild infection. No deaths were recorded. Viral genome sequencing confirmed four out of 12 cases with available genetic evidence. Risk of reinfection was estimated at 0.01% (95% CI: 0.01-0.02%) and incidence rate of reinfection was estimated at 0.36 (95% CI: 0.28-0.47) per 10,000 person-weeks.Conclusions SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of a strong protective immunity against reinfection that lasts for at least a few months post primary infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful for support provided by the Ministry of Public Health, Hamad Medical Corporation, and the Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core at Weill Cornell Medicine-Qatar. The statements made herein are solely the responsibility of the authors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were approved by Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data are available within the manuscript and appendix. ER -